By utilising a combination of rapid near patient and comprehensive high throughput laboratory based sexual health testing, you have the opportunity to create a tailored sexual health service to meet patient needs.
Roche sexual health solutions
Advanced STI testing solution
Create a tailored sexual health testing pathway
Right test, right place, right time
Sexually transmitted infection (STI) rates are rising rapidly – putting a strain on NHS services.1 Healthcare providers have opportunities to create STI pathways around patients – increasing access for at-risk groups.2
Roche Diagnostics is committed to developing advanced diagnostic solutions that address the challenges our sexual health services face, helping you to create a complete diagnostic pathway for sexually transmitted infections.
The comprehensive STI testing menu offered by the cobas® 5800/6800/8800 systems can be complemented by the rapid testing provided by cobas® liat STI assays to provide a tailored and targeted STI testing pathway for both laboratories and clinics.
Comprehensive laboratory-based and rapid point of care testing
BASHH Annual Conference, Stand 13
We will be attending the BASHH Annual Conference, 9-11th of June 2025 at the Edinburgh Conference Centre. Come and see us at Stand 13 to learn more about rapid STI testing on the cobas(r ball) liat system
Point of Care Testing
cobas® liat system
Targeted, near patient testing
Quick results for one or several suspected pathogens
- Rapid results for treatment within a single appointment window
Laboratory Solutions
cobas® 5800/6800/8800
Comprehensive sexual health testing menu
Routine efficiency for symptomatic and asymptomatic screening
Resistance testing to address the increasing threat of antimicrobial resistance (AMR)*
Both the cobas® liat system and cobas® 5800/6800/8800 assays offer a gold standard PCR result, regardless of the patient journey. Standardised collection device for both urine and vaginal swabs
* NG resistance and MG resistance in development. For research use only.
Rapid STI testing solutions for at-risk patients
Rapid Sexually Transmitted Infection (STI) assays on the cobas® liat system can bring testing closer to patients, providing clinically validated and accurate results for Chlamydia (CT), Gonorrhoea (NG) and Mycoplasma genitalium (MG) in just 20 minutes.5,6
Point of care STI tests are an important new tool that helps empowers clinicians, lab partners and local healthcare systems to create and shape new pathways around the needs and lifestyles of patients.
Clinicians have the opportunity to complement laboratory-based testing with priority testing for patients who are symptomatic, underserved, or at greatest risk of harm7, defining who, when, and where tests are clinically valuable and necessary.
Loss to follow up is a challenge all sexual health services face, with up to 30% of patients not returning for treatment following a positive diganosis8. Patients may be willing to wait 20 minutes for an STI result if they could be treated on the same day9. Those at risk of loss to follow up could be prioritised for rapid test and treat, helping reduce the risk of onward transmission and complications from untreated STIs7.
Test while they wait, treat before they leave.
Rapid POC tests for STIs provide a clinically actionable result in 20 minutes, which could help enable diagnostic confidence. Clinicians are in control, defining who, when and where tests are clinically valuable and necessary.
Test to know
Ability to diagnose upto three common STIs in a single appointment window5,6
Treat to go
Timely treatment may reduce the risk of onward transmission, reinfection, and the more serious consequences associated with untreated STIs8,10
Priority pathways
Rapid testing for clinic-defined at-risk populations
Simple to use
Gold standard PCR technology designed for the point of care environment5,6
Priority STI testing pathways for your patients and population
Roche rapid STI testing solutions help enable sexual health providers, lab partners and local healthcare systems to shape pathways around the needs and lifestyles of patients.
STI testing providers, labs and commissioners can help bring testing closer to patients, in line with NICE guidelines.
Rapid testing solutions for at-risk patients won’t replace existing arrangements but can be used when clinically appropriate.
Build targeted pathways around the specific needs of your patients and population
Design, implement and embed STI testing pathways for patients at risk of loss-of-follow-up.
Clinicians remain in control of when and where to use targeted testing technologies
Reduce AMR through improved antibiotic prescribing
Those diagnosed with an STI should receive treatment as quickly as possible.11 Failure to treat Chlamydia, Gonorrhoea, and Mycoplasma genitalium quickly and appropriately may contribute to the rising rates of AMR, posing a risk to patients and the population.7,10
Improved antibiotic prescribing may be achieved by utilising rapid test and treat for symptomatic patients and access to extended testing and resistance markers with cobas® 5800/6800/8800 MG resistance and NG resistance assays* and LGV assay^ for patients with a positive diagnosis. 7,10,11
* NG resistance and MG resistance in development. ^For research use only
Featured products
IVD
For in vitro diagnostic use.
cobas® liat system
The cobas® liat analyzer is an automated nucleic acid test instrument, that when used together with cobas® liat assay tubes to perform in vitro diagnostic tests, is referred to as the cobas® liat system. In conjunction with a cobas® liat assay tube, the instrument performs reagent preparation, target enrichment, inhibitor removal, nucleic acid extraction, polymerase chain reaction (PCR) amplification, real-time detection, and result interpretation to automate the detection or quantification of nucleic acid targets in a biological sample.
Addition for Canada only:
The cobas® liat system is intended for professional use in a clinical laboratory setting or Point of Care (POC) location.
Flexible, efficient and scalable sexual health solutions
A comprehensive sexual health testing menu is available on the Roche Molecular Work Area. Centred on the cobas® 5800/6800/8800 systems, the Molecular Work Area offers laboratories bespoke scalable testing solutions with options to incorporate automated pre-analytical systems, end-to-end tracking, and the digital technologies required to meet laboratories’ changing needs.
The cobas® 5800/6800/8800 systems are designed for flexible and scalable testing.7,8
Our cobas® 5800/6800/8800 systems address a variety of throughput needs and testing priorities with common assays, reagents, technology and user experience for consistent results, high performance and ease of use.
Comprehensive STI testing
Test today for the most common STIs and blood-borne viruses, with an expanded menu in development.
Bespoke molecular work area
Integrate diagnostic systems with pre-analytics, tracking and digital solutions to deliver scalable testing.
Efficient and flexible
True load and go with ready to use reagents, continuous random loading and flexible control concept.
Standardisation
Common assays, reagents and technology for consistent results, high performance and user friendly experience across systems.
*MG and NG resistance tests are in development
^MG and NG resistance and LGV assays are Research Use Only (RUO)
Comprehensive sexual health testing menu
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV) and Lymphogranuloma venereum (LGV)^ with an expanded menu in development.
Featured products
IVD
For in vitro diagnostic use.
cobas® 5800 System
The cobas® 5800 System makes automation, consolidation, integration and standardization more accessible than ever before.
IVD
For in vitro diagnostic use.
cobas® 6800 System
Embrace the future of molecular testing with proven PCR performance. Learn about the cobas® 6800 System’s broad menu of high-quality assays, including HIV, HPV, CT/NG, Hepatitis, CMV, WNV, respiratory infections, and more!
IVD
For in vitro diagnostic use.
cobas® 8800 System
Run up to 1,056 tests in an 8-hour shift and experience unparalleled automation - only 3 user interactions per run for up to 4 hours of walk-away time.
Keep Connected Control with Roche Digital Solutions
Digital technologies could help unlock new possibilities for decentralised patient-centric care
Choose from a suite of laboratory based and point of care digital solutions to build a digital ecosystem across centralised and decentralised testing environments.
navify® Lab Operations and navify® Analytics for Molecular
Together, our digital solutions provide full and transparent control over operations and turn operational data into actionable insights.
References
1. "Sexually Transmitted Infections and Screening for Chlamydia in England: 2023 Report.” GOV.UK,
2. “Recommendations: Reducing Sexually Transmitted Infections: Guidance.” NICE, Accessed 21 Jan. 2025. www.nice.org.uk/guidance/ng221/chapter/Recommendations#improvinguptake-and-increasing-the-frequency-of-sti-testing.
3. “Recommendations: Reducing Sexually Transmitted Infections: Guidance.” NICE, . Accessed 21 Jan. 2025. www.nice.org.uk/guidance/ng221/chapter/Recommendations#improvinguptake-and-increasing-the-frequency-of-sti-testing
4. Jensen, Jorgen S., and Magnus Unemo. “Antimicrobial Treatment and Resistance in Sexually Transmitted Bacterial Infections.” Nature News, Nature Publishing Group, 20 Mar. 2024, www.nature.com/articles/s41579-024-01023-3. Accessed 21 Jan. 2025.
5. cobas® liat CT/NG/MG package insert 10147563190-01EN Doc Rev. 1.0 October 2024
6. cobas® liat CT/NG package insert 10147580190-01EN Doc Rev. 1.0 October 2024
7. UK Health Security Agency. STI prioritisation framework. Available at: Accessed: March 2025. https://assets.publishing.service.gov.uk/media/67376f07abe1d74ea7dade2d/STIprioritisation-framework.pdf
8. Huppert JS, et al. Improving notification of sexually transmitted infections: a quality improvement project and planned experiment. Pediatrics. 2012;130(2):e415-22.
9. Widdice LE, Hsieh YH, Silver B, Barnes M, Barnes P, Gaydos CA. Performance of the Atlas Genetics Rapid Test for Chlamydia trachomatis and Women's Attitudes Toward Point-Of-Care Testing. Sex Transm Dis. 2018 Nov;45(11):723-727.
10. Jensen, Jorgen S., and Magnus Unemo. “Antimicrobial Treatment and Resistance in Sexually Transmitted Bacterial Infections.” Nature News, Nature Publishing Group, 20 Mar. 2024
11. British Association for Sexual Health and HIV (BASHH). Standards for STI management. Available at: https://www.bashh.org/_userfiles/pages/files/bashhstandardsforstimanagement2019.pdf Accessed: Jan 2025.